This Combined Synopsis/Solicitation opportunity from Department Of Health And Human Services was posted on April 8, 2025. The submission period has ended. Browse the details below for market research, or find similar active opportunities.

Top

ADULT COVID-19 2025-2026

Closed

75D30125R00117Federal

Submission Closed04/15/2025, 09:00:00 PM UTC

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

Active Opportunities Like This One

NAICS: 325412

New

International

Pralidoxime Chloride/Methyl Sulfate ManufacturingThis subcontract involves the manufacture and supply of Pralidoxime chloride or methyl sulfate in solution or powder form for injection to support prime contractors on Department of National Defence projects. The required product must have a dosage strength of at least 200 mg per container and a minimum shelf-life of 36 months. The selected provider is responsible for conducting stability testing, providing quality assurance certification, and delivering complete treatment courses along with stability reports and product monographs. To be eligible, the manufacturer must hold a Health Canada Notice of Compliance under Division 8 or Division 11 authorization. This global procurement opportunity is managed by the Government of Canada and allows for performance across various international regions. Interested parties must submit their responses by November 10, 2026.

Department of National Defence

POSTED

DEADLINE

SLS Printer Consumables and Maintenance KitsThis subcontract focuses on the provision of specialized consumables and wear-and-tear replacement parts to support prime contractors working on Department of National Defence projects for the Government of Canada. The scope of supply includes engineering-grade thermoplastic powders such as PA 11, PA 12, PP, and TPU, along with critical SLS hardware components including optical cassettes, recoater blades, infrared heaters, sealing foam gaskets, and build chambers. All bulk consumables and spare parts kits are to be delivered to CFB Petawawa. The opportunity was posted on October 20, 2026, with a response deadline of November 2, 2026, falling under NAICS code 325412.

Department of National Defence

POSTED

DEADLINE

Supplier of Red Sealing Compound (NSN 8030015650423)This subcontract involves the supply of red sealing compound, identified by NSN 8030015650423, for prime contractors working under the Defense Logistics Agency. The material must be provided in 10.00 milliliter containers and strictly adhere to the DLA Master List of Technical and Quality Requirements RA001. The supplier is responsible for managing TYPE I (CODE H) shelf-life requirements and ensuring all packaging complies with MIL-STD-2073-1E and MIL-STD-129 standards. Additionally, the contractor must provide all necessary safety documentation, including SDS and HazCom labels in accordance with 29 C.F.R. 1910.1200. The performance of this contract is centered in FPO 09591-0100, with the primary objective being the delivery of packaged sealing compound and its associated safety certifications to the Department of Defense.

Defense Logistics Agency

POSTED

DEADLINE

Active Pharmaceutical Ingredient (API) SupplyThis subcontract for Active Pharmaceutical Ingredient (API) Supply involves the synthesis, purification, and bulk delivery of pharmaceutical-grade Benzocaine and Menthol. The provider supports prime contractors fulfilling requirements for the Department of Defense Medical Supply Chain Pharm FSA, ensuring all raw chemical components meet strict USP and ISO manufacturing standards through the use of HPLC purity testing. The performance of this contract is centered at Fort Campbell, Kentucky, under NAICS code 325412. The solicitation was posted on October 19, 2026, with a response deadline of October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Benzocaine and Menthol Lozenge SupplyThis subcontract involves the manufacture and supply of finished Benzocaine and Menthol lozenges to prime contractors supporting the Department of Defense Medical Supply Chain Pharm FSA. The provider is responsible for producing and quality-testing pharmaceutical lozenges within FDA-compliant facilities adhering to Good Manufacturing Practice standards to ensure all delivered quantities meet strict government specifications. Administrative processes for this requirement are managed through the DLA Internet Bid Board System for quote submissions. The performance of the contract is centered at Fort Campbell, and the procurement falls under NAICS code 325412 for pharmaceutical preparation.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Moxifloxacin Hydrochloride Tablets (400 MG)This subcontract, managed by the Medical Supply Chain Pharm FSA under the Department of Defense, involves the manufacture and supply of pharmaceutical-grade Moxifloxacin Hydrochloride Tablets (400 MG). The contractor is responsible for providing the antibiotic tablets in 30-count bottles, ensuring all products are sourced or manufactured in accordance with Good Manufacturing Practices and FDA approval and registration requirements. Logistical compliance is critical, as the contract mandates adherence to RP001 DLA Packaging Requirements and the use of climate-controlled storage and transport to maintain product integrity. Performance will take place in FPO 09591, with the primary objective of supporting prime contractors on DLA supply contracts.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Activated Charcoal, SuspensionThis subcontract, issued by the Medical Supply Chain Pharm FSA under the Department of Defense, requires the provision of activated charcoal in suspension form, identified by NSN 6505012828880. The materials must be delivered to the USS Lewis B Puller ESB 3, with all shipments adhering to strict DLA packaging requirements and technical specifications. The contract falls under NAICS code 325412 and is intended for prime contractors supporting DLA supply operations. Resellers are specifically required to comply with the Non-Manufacturer Rule to ensure eligibility. The performance location is designated as FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of 4% Chlorhexidine Gluconate Surgical DetergentThis subcontract involves the supply of FDA-regulated 4% Chlorhexidine Gluconate surgical detergent for prime contractors supporting Department of Defense supply contracts. The provider is responsible for manufacturing or sourcing the chemical compound in strict accordance with NSN 6505-01-101-3759 specifications and DLA Packaging Requirements RP001. To maintain quality and regulatory compliance, the product must be produced in FDA-approved pharmaceutical manufacturing facilities. The contract mandates a total shelf life of 24 months, with a requirement that the detergent possesses at least 21 months of remaining shelf life at the time of delivery. Managed under the Medical Supply Chain Pharm FSA, the performance of this contract is centered in FPO 96660, falling under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Bupivacaine and Epinephrine InjectionThis subcontract involves the supply of Bupivacaine and Epinephrine Injection to prime contractors supporting DLA Troop Support medical supply contracts. The provider must deliver end items compliant with NSN 6505-01-189-3973, utilizing pharmaceutical-grade materials and medical-grade packaging. To qualify, the supplier is required to hold all necessary pharmaceutical manufacturing licenses and maintain FDA approval for the specific drug formulation. Managed by the Department of Defense under the Medical Supply Chain Pharm FSA, the contract specifies the delivery of injectable medication quantities as outlined in the award. The performance location is designated as FPO 09591, and the procurement falls under NAICS code 325412.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Isoniazid Tablet ManufacturingThis subcontract involves the manufacturing of Isoniazid 300 MG tablets for prime contractors supporting Department of Defense pharmaceutical supply contracts through the Medical Supply Chain Pharm FSA. The manufacturer is responsible for producing tablets that conform to United States Pharmacopeia standards, packaged in bottles of 100 units. To execute this contract, the provider must utilize pharmaceutical grade API, specialized tablet pressing equipment, and a USP-compliant quality control laboratory. Strict regulatory adherence is required, including the maintenance of active FDA registration and continuous USP compliance. The performance of this contract is centered in FPO 09591, with the primary objective of delivering finished pharmaceutical products that meet all specified government quality and safety benchmarks.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Tetrahydrozoline Hydrochloride Ophthalmic Solution SupplierThis subcontract involves the supply of Tetrahydrozoline Hydrochloride Ophthalmic Solution, USP (0.05%, 15 ML) to support prime contractors under DLA Troop Support medical supply contracts. The selected provider is responsible for manufacturing or sourcing the pharmaceutical solution in accordance with USP standards, utilizing sterile ophthalmic bottling and packaging. All operations must comply with FDA approval and registration requirements for pharmaceutical manufacturing. The contract is managed by the Department of Defense under the Medical Supply Chain Pharm FSA. Physical deliveries of the ophthalmic solution are to be made to either the prime contractor or the Naval Med Readiness Logistics Command, with the place of performance located in Williamsburg, Virginia.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

DEADLINE

Supply of Tolnaftate Powder, USP 1%This subcontract through the Department of Defense Medical Supply Chain Pharm FSA involves the supply of Tolnaftate Powder, USP 1%, to prime contractors on DLA Troop Support medical supply contracts. The requirement is for 15 bottles of 45 GM powder, identified by NSN 6505014807897, which must strictly adhere to USP 1% standards and the DLA Master List of Technical and Quality Requirements. Eligible providers must possess the necessary pharmaceutical manufacturing and distribution licenses to fulfill the order. The performance of this contract is designated for FPO 09591, with a response deadline set for October 26, 2026.

MEDICAL SUPPLY CHAIN PHARM FSA

POSTED

2 days ago

DEADLINE

in 5 days

AI Contract Overview

The CDC is seeking to establish one or more Indefinite Delivery Indefinite Quantity contracts to acquire all U.S.-licensed or authorized COVID-19 vaccines with adult indications. These contracts aim to leverage Section 317 vaccine purchase funds to secure vaccines at prices below commercial market rates, supporting state and local health departments in vaccinating populations at highest risk for under-vaccination and disease. The vaccines purchased under these contracts will primarily serve the immunization programs managed by the National Center for Immunization and Respiratory Diseases, including fifty state health departments, large city programs, and U.S. territories, in accordance with the Public Health Service Act. Awardees may also choose to purchase additional vaccine quantities using their own funds, enhancing adult immunization efforts. The solicitation, titled "ADULT COVID-19 2025-2026," was posted on April 8, 2025, with a response deadline of April 22, 2025. It is managed by the CDC Office of Acquisition Services under the Department of Health and Human Services, located in Atlanta, Georgia. Interested parties can contact representatives Brian Swann and James Sprigler via email for further information. The contract aims to ensure the availability of COVID-19 vaccines to support ongoing immunization initiatives, with the potential for flexible procurement to meet public health needs during the specified period.

General Info

Contract for COVID-19 pharmaceutical preparations active until May 7, 2025; Georgia location.

Agency

Department Of Health And Human Services → CDC Office Of Acquisition Services

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Place of Performance

GA, 30341, USA

Set-Aside

NONE

Documents

Solicitation 75D30125R00117 - COVID-19 Adult Vaccines

rfp

High

Attachment+1+-+Vaccine+Order+Limitation+Chart.docx

Attachment+2+-+ADR+Agreement.docx

Solicitation+75D30125R00117+COVID19+Adult+Pages+2-50.docx

AI Contract Breakdown

Uniform Contract Format

Contract not broken down yet

CLEATUS splits the solicitation into Uniform Contract Format (UCF) sections: scope, pricing, deliverables, and evaluation criteria.

Timeline

1 update

PhaseClosed

PostedApr 8

Combined Synopsis

Deadline changedApr 8

Response deadline changed from Apr 15, 2025 to Apr 22, 2025.

Response DeadlineApr 15

Deadline has passed

Submission Closed

04/15/2025, 09:00:00 PM UTC

Find active opportunities like this

Start your free trial to discover similar active contracts, track opportunities, and build proposals with AI assistance.

Organization & Contact Information

AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

Contacts2 people available

OfficeATLANTA, GA, 30333, USA

Organization / AgencyDepartment Of Health And Human Services → CDC Office Of Acquisition Services

Office AddressATLANTA, GA, 30333, USA

Contacts

Brian Swann

contact@example.gov

James Sprigler

contact@example.gov

Full Description

The Centers for Disease Control and Prevention (CDC) is seeking to award one or more Indefinite Delivery Indefinite Quantity (IDIQ) contracts for the purchase of all U.S-licensed or authorized COVID-19 brands with an adult indication. The establishment of these contracts provides opportunity to utilize Section 317 vaccine purchase funds to obtain vaccines at prices below those available in the commercial market place. These funds provide vaccines for state and local health departments to use in populations at greatest risk for under vaccination and disease. The 317 program as established under Section 317(j) of the Public Health Service Act, works to ensure that adults receive appropriate immunization by partnering with healthcare providers in the public and private sectors. The program helps assure the implementation of effective immunization practices and proper use of vaccines to achieve higher immunization coverage. The vaccines awarded under these contracts will be purchased for the National Center for Immunization and Respiratory Disease's (NCIRD's) immunization awardees (the fifty state health departments, several large city programs and current and former U.S. Territories) to support adult immunization programs as provided under Section 317(j) of the Public Health Service Act. In addition, awardees may opt to purchase additional quantities of vaccine for adults under any resulting contract using state and local funds.